Abstract P5-15-03:nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Randomized Phase 2 ◽

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05070-2 ◽

2018 ◽

Vol 174 (2) ◽

pp. 433-442 ◽

Cited By ~ 17

Author(s):

O. Nanni ◽

◽

D. Amadori ◽

A. De Censi ◽

A. Rocca ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Clinical Trial ◽

Randomized Phase 2 ◽

5060 POSTER Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial

European Journal of Cancer ◽

10.1016/s0959-8049(11)71502-7 ◽

2011 ◽

Vol 47 ◽

pp. S348

Author(s):

W.J. Gradishar ◽

D.A. Krasnojon ◽

S.V. Cheporov ◽

A.N. Makhson ◽

G.M. Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.610 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 610-610 ◽

Cited By ~ 3

Author(s):

Ahmad Awada ◽

Ramon Colomer ◽

Igor Bondarenko ◽

Kenichi Inoue ◽

Rajendra A. Badwe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

Abstract OT3-1-11: tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer

10.1158/0008-5472.sabcs13-ot3-1-11 ◽

2013 ◽

Cited By ~ 1

Author(s):

DA Yardley ◽

A Brufsky ◽

P Conte ◽

J Cortes ◽

S Glück ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Annals of Oncology ◽

10.1093/annonc/mdy201 ◽

2018 ◽

Vol 29 (8) ◽

pp. 1763-1770 ◽

Cited By ~ 30

Author(s):

D.A. Yardley ◽

R. Coleman ◽

P. Conte ◽

J. Cortes ◽

A. Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.12.012 ◽

2020 ◽

Vol 20 (3) ◽

pp. 228-237 ◽

Cited By ~ 1

Author(s):

Noha Rashad ◽

Thoraya Abdelhamid ◽

Samia A. Shouman ◽

Hanan Nassar ◽

Mervat A. Omran ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

10.1158/1538-7445.sabcs14-ot2-2-01 ◽

2015 ◽

Author(s):

Denise A Yardley ◽

Robert E Coleman ◽

Pierfranco Conte ◽

Joyce O'Shaughnessy ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Cited By ~ 16

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Locally Recurrent ◽

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer

Oncotarget ◽

10.18632/oncotarget.18539 ◽

2017 ◽

Vol 8 (45) ◽

pp. 79527-79536 ◽

Cited By ~ 2

Author(s):

Jian Zhang ◽

Leiping Wang ◽

Zhonghua Wang ◽

Biyun Wang ◽

Jun Cao ◽

...

Keyword(s):

Breast Cancer ◽

Low Dose ◽

Triple Negative ◽

Metastatic Breast ◽

Oral Cyclophosphamide ◽

Line Treatment ◽

First Line ◽

Tnacity: a Phase Ii/Iii Trial of Nab-Paclitaxel (Nab-P) Plus Either Gemcitabine (Gem) or Carboplatin (Carbo) Vs Gem/Carbo As First-Line Treatment for Triple-Negative Metastatic Breast Cancer (Tnmbc)

Annals of Oncology ◽

10.1093/annonc/mdu329.62 ◽

2014 ◽

Vol 25 ◽

pp. iv135

Author(s):

P.F. Conte ◽

D.A. Yardley ◽

A. Brufsky ◽

R.E. Coleman ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽